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Abstract
Several studies showed that assessing levels of specific circulating microRNAs (miRNAs) is a non-invasive, rapid, and
accurate method for diagnosing diseases or detecting alterations in physiological conditions. We aimed to identify a serum
miRNA signature to be used for the diagnosis of tuberculosis (TB). To account for variations due to the genetic makeup, we
enrolled adults from two study settings in Europe and Africa. The following categories of subjects were considered: healthy
(H), active pulmonary TB (PTB), active pulmonary TB, HIV co-infected (PTB/HIV), latent TB infection (LTBI), other pulmonary
infections (OPI), and active extra-pulmonary TB (EPTB). Sera from 10 subjects of the same category were pooled and, after
total RNA extraction, screened for miRNA levels by TaqMan low-density arrays. After identification of ‘‘relevant miRNAs’’, we
refined the serum miRNA signature discriminating between H and PTB on individual subjects. Signatures were analyzed for
their diagnostic performances using a multivariate logistic model and a Relevance Vector Machine (RVM) model. A leave-
one-out-cross-validation (LOOCV) approach was adopted for assessing how both models could perform in practice. The
analysis on pooled specimens identified selected miRNAs as discriminatory for the categories analyzed. On individual serum
samples, we showed that 15 miRNAs serve as signature for H and PTB categories with a diagnostic accuracy of 82% (CI 70.2–
90.0), and 77% (CI 64.2–85.9) in a RVM and a logistic classification model, respectively. Considering the different ethnicity, by
selecting the specific signature for the European group (10 miRNAs) the diagnostic accuracy increased up to 83% (CI 68.1–
92.1), and 81% (65.0–90.3), respectively. The African-specific signature (12 miRNAs) increased the diagnostic accuracy up to
95% (CI 76.4–99.1), and 100% (83.9–100.0), respectively. Serum miRNA signatures represent an interesting source of
biomarkers for TB disease with the potential to discriminate between PTB and LTBI, but also among the other categories.
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Introduction
Tuberculosis (TB) remains one of the most relevant infectious
diseases with nearly 9 million cases and 1.4 million deaths per year
worldwide [1]. Due to the complexity of the clinical presentations
of the infection caused by members of the Mycobacterium tuberculosis
complex (latent asymptomatic infection, active pulmonary and/or
extra-pulmonary disease), accurate classification of cases is
essential to address the most appropriate clinical management
[2–4].
Current standards for TB diagnosis, including the most sensitive
molecular tests, rely on the detection of the pathogen, thus being
dependent on the bacterial load in the specimen analyzed; indeed,
diagnosing TB in children is a difficult task because the
mycobacterial load is often low [5–7]. Similarly, extra-pulmonary
TB (EPTB) cases are often challenging to diagnose due to the
difficulties in obtaining samples for microbiological investigations,
and are affected by unpredictable distribution of bacteria in
tissues. Therefore, EPTB and smear-negative pulmonary TB
(PTB) are usually diagnosed ex juvantibus. Finally, despite the
importance of utterly discriminating between latent TB infection
(LTBI) and active TB, clear-cut biological markers separating the
two conditions are not yet available [8–10]. Biomarkers and
surrogate endpoints are therefore crucial tools for the development
of innovative strategies for TB management [11].
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The development of diagnostic tests based on host biomarkers is
advocated to clinically categorize paucibacillary or not microbi-
ologically-confirmed TB cases, and for proper identification of
LTBI cases [11,12]. The need for biomarkers extends beyond the
urgency for improved diagnostic tools: the assessment of the
disease status and of the risk of progression to active disease or the
assessment of treatment success early during therapy are critical
bottlenecks in the development of new vaccines and drugs, and
could allow categorization of therapy based on individual risk of
unfavorable outcome.
The ideal biomarker should be a stable molecule, and should be
in sufficient amounts for easy detection in accessible body fluids
[9,13]. The discovery that human microRNAs (miRNAs) expres-
sion is frequently altered in various diseases has uncovered a new
Figure 1. Criteria for the inclusion in the study population.
doi:10.1371/journal.pone.0080149.g001
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repertoire of molecular factors, which warrants investigation to
further elucidate their role in physiology and disease [14]. In the
cell, miRNAs post-transcriptionally regulate the expression level of
target genes [15]. The miRNA highly-conserved regulatory system
does not remain confined to the intracellular compartment: they
can be transferred via body fluids (including plasma, serum, urine,
and saliva), thus modulating translational responses by intercellu-
lar communication [16–19].
miRNAs could represent an ideal biomarker, owing to the
sampling easiness, the inherent stability and the resilience [19,20].
However, their characterization during viral or bacterial infection
has raised interest only recently, and data on TB remain limited to
few studies [21–23].
This research aimed at identifying miRNA profiles associated
with the different phases of M. tuberculosis infection (PTB, EPTB,
LTBI), and non-tubercular lung infections as well as in healthy
condition and showing their use as specific signatures for PTB
diagnosis.
Materials and Methods
Ethical Statements
The protocol of the study was approved by the Ethical
Committee of the San Raffaele Scientific Institute, Milano, Italy
(GO/URC/ER/mm prot. N. 82/DG) and of the participating
institutions in Uganda and Tanzania. The study was conducted in
full compliance with the principles of the Declaration of Helsinki.
All samples were collected from individuals who had signed an
informed consent form for the purpose of the study and for
cryopreservation of their biological samples.
Study Population
The following case definitions were adopted to categorize
individuals enrolled in the study:
– Patients with active pulmonary TB (PTB): sputum smear
microscopy positive for acid-fast bacilli, M. tuberculosis complex
culture and/or Xpert MTB/RIF (Cepheid, Sunnyvale, CA)
positive patients with pulmonary disease, HIV negative
individuals;
– Patients with active pulmonary TB and HIV co-infection
(PTB/HIV): sputum smear microscopy positive for acid-fast
bacilli, M. tuberculosis complex culture and/or Xpert MTB/RIF
positive patients with pulmonary disease, HIV positive
confirmed cases;
– Patients with active extra-pulmonary TB (EPTB): culture
positive TB cases with any extra-pulmonary disease localiza-
tion, HIV negative individuals;
– Latent TB infection cases (LTBI): subjects who resulted
interferon-c release assay (IGRA) or tuberculin skin test
(TST) positive with no signs/symptoms of active disease;
– Subjects affected by pulmonary infectious diseases other than
TB (OPI): clinical diagnosis (clinical exam plus imaging), with
or without microbiological confirmation, IGRA and/or TST
negative;
– Healthy subjects (H): IGRA and/or TST negative, without any
known risk factors for LTBI, without any clinically relevant
conditions.
The study populations of adult subjects were enrolled between
September 2009 and December 2012 from two studies, namely
TBnew and TB CHILD.
TBnew. Subjects enrolled at the San Raffaele Hospital
(Milano, Italy), Spedali Civili of Brescia (Brescia, Italy), Regional
Center for TB ‘‘Villa Marelli’’, Niguarda Hospital (Milano, Italy),
and at the National Institute for Infectious Diseases ‘‘L.
Spallanzani’’ (Roma, Italy) belonged to the following categories:
PTB, EPTB, LTBI, H, OPI.
TB CHILD. Subjects enrolled at Ifakara Health Institute -
Bagamoyo Research and Training Centre (BRTC) (Pwani,
Tanzania), NIMR-Mbeya Medical Research Programme
(MMRC) (Mbeya, Tanzania), and at the St. Francis Nsambya
Hospital (Kampala, Uganda) belonged to the following categories:
PTB, PTB/HIV, H.
Figure 2. Demographic data of the TBnew and the TB CHILD populations. The Figure reports mean age for the categories of subjects enrolled
and distribution of the country of birth in the different World Health Organization regions.
doi:10.1371/journal.pone.0080149.g002
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All subjects included in the study underwent the following
procedures:
– phlebotomy through a 21G butterfly device to minimize
hemolysis during specimen collection. Additive-free blood
collection tubes were chosen to minimize unwanted modifica-
tion of miRNA content in the serum;
– collection of clinically relevant data to determine TB status
(with relevant confirmatory exams), and HIV status. A
questionnaire to capture any additional information such as:
pregnancy, smoking, current medical problems (diabetes,
transplant, silicosis, sarcoidosis, cancer), current therapies with
particular focus on immunosuppressive, antiretroviral and anti-
TB ones was compiled for all patients during enrolment.
All information was stored in an electronic data-protection
system.
Enrolment and exclusion criteria of the study population are
summarized in Figure 1.
Figure 3. Summary of candidate serummiRNAs selected as relevant to discriminate among the categories according to the analysis
of pooled specimens. Population and category of pooled specimens are reported on the circumference. The thickness of the ribbons connecting
two categories is proportional to the number of miRNAs potentially interesting in the discrimination between the categories linked.
doi:10.1371/journal.pone.0080149.g003
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Serum Preparation
Within 4 hours from time of phlebotomy, after coagulation,
tubes were centrifuged at 2500 rpm for 10 minutes, with
separation of serum from corpuscular fractions. Subsequently,
serum fraction was transferred – in sterile environment – into
15 mL tubes and underwent a second centrifugation at 2800 rpm
for 10 minutes, in order to achieve maximum removal of cellular
component. Serum was hence transferred in aliquot of 1 mL into
cryogenic vials and stored at 280uC. For RNA extraction, sera
were thawed on ice and the degree of hemolysis was determined
through spectrometry analysis of free hemoglobin as previously
described [24]. A cut-off value of hemoglobin concentration of
.10 mg/dL was considered for hemolyzed samples.
Figure 4. Summary of putative serummiRNA signatures discriminating among relevant clinical categories according to the analysis
of pooled specimens. Clinical category and miRNAs are reported on the circumference. The ribbons represent the connection between miRNAs
and clinical categories. The serum miRNAs have been defined by the following filters: Infection: H vs PTB, H vs LTBI, H vs EPTB, H vs PTB/HIV, OPI vs
PTB, OPI vs LTBI, OPI vs EPTB; Active TB: H vs PTB, H vs EPTB, H vs PTB/HIV, OPI vs PTB, OPI vs EPTB, LTBI vs PTB, LTBI vs EPTB; Symptoms: H vs PTB, H vs
OPI, H vs PTB/HIV, H vs EPTB, LTBI vs PTB, LTBI vs EPTB, LTBI vs OPI; Pulmonary disease (any): H vs PTB, H vs OPI, H vs PTB/HIV, LTBI vs PTB, LTBI vs OPI,
EPTB vs PTB, EPTB vs OPI.
doi:10.1371/journal.pone.0080149.g004
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Table 1. Serum miRNAs showing different levels in healthy (H) and pulmonary active tuberculosis (PTB) subjects from the two
populations included in the study.
miRNA Array TBnew vs TB CHILD (p-val) H vs PTB (p-val)
has-miR-155-4395459 A 0,01375 0,40055
hsa-miR-126-4395339 A 0,02580 0,76655
hsa-miR-129-5p-4373171 A 0,02600 0,84640
hsa-miR-139-3p-4395424 A 0,00975 0,91465
hsa-miR-142-5p-4395359 A 0,00025 0,33310
hsa-miR-145-4395389 A ,0,00001 0,88630
hsa-miR-146b-5p-4373178 A 0,02525 0,10360
hsa-miR-148b-4373129 A 0,00170 0,84365
hsa-miR-150-4373127 A 0,01065 0,37600
hsa-miR-152-4395170 A ,0,00001 0,43940
hsa-miR-17-4395419 A 0,00630 0,50405
hsa-miR-184-4373113 A 0,00510 0,32595
hsa-miR-195-4373105 A ,0,00001 0,16715
hsa-miR-19a-4373099 A 0,04110 0,34870
hsa-miR-20b-4373263 A 0,00315 0,52460
hsa-miR-220c-4395322 A 0,00100 0,29480
hsa-miR-29c-4395171 A 0,02855 0,29935
hsa-miR-302c-4378072 A ,0,00001 0,55550
hsa-miR-324-3p-4395272 A 0,00805 0,75735
hsa-miR-331-3p-4373046 A 0,00455 0,43190
hsa-miR-374b-4381045 A 0,00745 0,36145
hsa-miR-423-5p-4395451 A 0,04475 0,15395
hsa-miR-485-3p-4378095 A ,0,00001 0,54070
hsa-miR-574-3p-4395460 A 0,04470 0,05040
hsa-miR-597-4380960 A 0,00025 0,98915
hsa-miR-628-5p-4395544 A 0,01450 0,32615
hsa-miR-744-4395435 A 0,00100 0,40245
hsa-miR-872-4395375 A ,0,00001 0,06135
hsa-miR-9-4373285 A 0,04985 0,21925
MammU6-4395470 A 0,00140 0,51640
hsa-miR-135a*-4395343 B 0,00020 0,22165
hsa-miR-509-3p-4395347 B 0,01160 0,19885
hsa-miR-645-4381000 B 0,00005 0,27560
hsa-miR-801-4395183 B ,0,00001 0,87435
hsa-miR-923-4395264 B 0,00080 0,06465
MammU6-4395470 B 0,00045 0,58190
hsa-let-7e-4395517 A 0,80890 0,00395*
hsa-miR-10b-4395329 A 0,79615 0,0072*
hsa-miR-127-5p-4395340 A 0,96665 0,00495*
hsa-miR-130a-4373145 A 0,09690 0,02485
hsa-miR-146a-4373132 A 0,14045 0,0047*
hsa-miR-148a-4373130 A 0,91780 ,0,00001*
hsa-miR-16-4373121 A 0,17145 0,00045*
hsa-miR-185-4395382 A 0,47350 0,00685*
hsa-miR-19b-4373098 A 0,42240 0,01720
hsa-miR-24-4373072 A 0,29355 0,04625
hsa-miR-25-4373071 A 0,18345 0,00065*
hsa-miR-27a-4373287 A 0,19845 0,01235
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Serum Pools
Each pool for qRT-PCR analysis was composed of 10 non-
smoker subjects from the same category, equally distributed by
gender. Selected subjects were free of co-morbidities (as for the
pathologies investigated during the enrolment interview) to avoid
confounding effects on miRNA profiles. A serum aliquot from
each subject was thawed on ice, and 500 mL of serum from each
sample were mixed together in order to obtain a homogeneous
pooled serum sample. One mL of pooled serum was used for RNA
extraction and subsequent miRNA analysis in duplicate.
Serum from Single Individuals
To refine the results obtained from pooled sera, we performed
individual serum analysis on 18 subjects belonging to the PTB and
Figure 5. Analysis of the results of serummiRNAs in healthy controls (H) and pulmonary active tuberculosis (PTB) using pooled and
individual specimens. Squares summarize results obtained by comparison of miRNAs in pooled specimens, whereas circles define results from
individual sera.
doi:10.1371/journal.pone.0080149.g005
Table 1. Cont.
miRNA Array TBnew vs TB CHILD (p-val) H vs PTB (p-val)
hsa-miR-27b-4373068 A 0,12255 0,03670
hsa-miR-342-3p-4395371 A 0,77485 0,01620
hsa-miR-365-4373194 A 0,48025 0,00345*
hsa-miR-374a-4373028 A 0,17845 0,03010
hsa-miR-376c-4395233 A 0,32505 0,04740
hsa-miR-451-4373360 A 0,50895 0,0082*
hsa-miR-532-5p-4380928 A 0,09210 0,00155*
hsa-miR-590-5p-4395176 A 0,46820 0,0039*
hsa-miR-660-4380925 A 0,48025 0,00095*
hsa-miR-885-5p-4395407 A 0,86025 0,003*
RNU48-4373383 A 0,90280 0,02350
hsa-miR-144*-4395259 B 0,63015 0,02595
hsa-miR-223*-4395209 B 0,79420 0,00025*
hsa-miR-30a-4373061 B 0,14410 0,00065*
hsa-miR-30a*-4373062 B 0,54630 0,03605
hsa-miR-30d-4373059 B 0,43060 0,00715
hsa-miR-30e-4395334 B 0,50865 0,0012*
hsa-miR-106a-4395280 A 0,03535 0,01145
hsa-miR-125a-5p-4395309 A 0,00380 0,03295
hsa-miR-192-4373108 A 0,04850 0,001*
hsa-miR-193a-5p-4395392 A 0,01675 0,00485*
hsa-miR-212-4373087 A ,0,00001 0,02215
hsa-miR-483-5p-4395449 A 0,00120 0,03800
hsa-miR-518d-3p-4373248 A 0,03350 0,00155*
*miRNAs showing a p-adj ,0.05.
doi:10.1371/journal.pone.0080149.t001
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H categories from the TBnew group, and on 10 subjects from the
TB CHILD group. As for pooled sera, individuals were selected
free of co-morbidities among non smokers. A serum aliquot from
each subject was thawed on ice, and 1 mL of serum from each
individual was used for RNA extraction and subsequent miRNA
analysis.
RNA Extraction
RNA extraction was performed using the mirVana miRNA
isolation kit (Life Technologies) according to the manufacturer’s
instructions for isolating total RNA. RNA samples were stored at
280uC until use.
Serum miRNA Profiling
Serum miRNAs analysis was performed with TaqManH Low
Density Array (TLDA) Human MicroRNA Panels A and B,
investigating an overall of 671 different miRNAs (Life Technol-
ogies). Retro-transcription was performed with TaqManH micro-
RNA reverse transcription kit and MegaPlex RT Primers Human
Pool A v2.1 and B v2.0 components (Life Technologies), according
to the manufacturer’s instructions. For each RT reaction 15 ng of
total RNA were used. After RT step, samples were pre-amplified
using the MegaPlex PreAmp Primers A and B and the TaqManH
PreAmp Mater Mix according to the manufacturer’s instructions
(Life Technologies). TLDAs were performed using a 7900HT Fast
Real-Time PCR System or a ViiATM 7 Real-Time PCR System
according to manufacturer’s instructions (Life Technologies). On
pooled sera, we performed analyses in biological and technical
replicate for each array panel (A and B), whereas for each
individual sera we performed single arrays (panels A+B).
Data Analysis and Normalization
Data from TaqManH were collected with SDS v2.4.1, ViiATM 7
v1.1, and RQ Manager v1.2.2 software (Applied Biosystems),
(baseline: automatic; threshold: 0.20; maximum allowable Ct:
35.0). Data analysis was performed in R and Bioconductor
environment [25]. We first preprocessed raw Ct values by means
of quantile normalization, as described elsewhere [26–28]. This
widely used approach is based on the assumption that only few
miRNAs are differentially expressed. As a general result, this
method provides homogenous data with the same distribution and
the correlation coefficient between observations increases com-
pared to raw data. Normalized data distribution was graphically
inspected.
Statistical Analysis
Results from pools and individuals were analyzed separately.
Pools. We performed one-to-one category comparisons be-
tween mean Ct values fitting a constrained regression model with
MM robust estimators [29,30]. These robust estimates have a high
breakdown-point and are not affected by the presence of outliers
or differently expressed miRNAs. We then computed the
Empirical Distribution Function of residuals and filtered miRNAs
associated with residuals outside the Inter Quartile range (i.e.
outside the 1st quartile –3rd quartile interval) of the residuals
distribution and we defined them as ‘‘interesting miRNAs’’ or
‘‘relevant miRNAs’’. Circular visualization of data was made by
Circos software [31].
Individuals. As our first step we filtered out miRNAs
detected Ct,35 in at least $80% of subjects of at least one of
the categories considered (H in TBnew, PTB in TBnew, H in TB
CHILD, and PTB in TB CHILD). For these filtered out miRNAs
we performed a two ways ANOVA for health status and genetic
makeup (defined as for country of birth). P-values were computed
non-parametrically by means of permutations [32]. We checked
for False Discovery Rate (FDR) with the method described by
Benjamini and Yekutieli [33]. miRNAs showing both (i) an
adjusted p-value (p-adj) ,0.05 on individuals and (ii) relevant by
Table 2. Serum miRNA levels in pulmonary active tuberculosis (PTB) subjects as compared with healthy controls (H).
TBnew TB CHILD Combined
miRNAs p-adj ,0.05 Individuals Pools Individuals Pools Individuals Pools
Relevance in pooled
specimens To be considered for
hsa-let-7e-4395517 TBnew, TB CHILD TBnew, TB CHILD
hsa-miR-146a-4373132 6 TB CHILD only TB CHILD only
hsa-miR-148a-4373130 TBnew, TB CHILD TBnew, TB CHILD
hsa-miR-16-4373121 TBnew only TBnew only
hsa-miR-192-4373108 TBnew, TB CHILD TBnew, TB CHILD
hsa-miR-193a-5p-4395392 TBnew, TB CHILD TBnew, TB CHILD
hsa-miR-25-4373071 TBnew only TBnew only
hsa-miR-365-4373194 6 TBnew only TBnew only
hsa-miR-451-4373360 TBnew, TB CHILD TBnew, TB CHILD
hsa-miR-532-5p-4380928 6 TB CHILD only TB CHILD only
hsa-miR-590-5p-4395176 TBnew, TB CHILD TBnew, TB CHILD
hsa-miR-660-4380925 TB CHILD only TB CHILD only
hsa-miR-885-5p-4395407 TBnew, TB CHILD TBnew, TB CHILD
hsa-miR-223*-4395209 TB CHILD only TB CHILD only
hsa-miR-30a-4373061 6 6 6 TBnew, TB CHILD –
hsa-miR-30e-4395334 6 6 TBnew, TB CHILD TB CHILD only
The table reports data from individual and pooled specimens. Discrepancies are marked by x.
doi:10.1371/journal.pone.0080149.t002
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pooled specimens analysis were considered for miRNA signature
definition.
Performances of the signature. To assess the single
miRNA performance in identifying health status a Receiver
Operating Characteristic (ROC) curve based on kernel density
distributions method fit as described in [34]. As overall measures
of the performance in distinguish cases, the associated Area under
the curve (AUC) was calculated and the p-values computed by
means of permutations.
To assess and compare diagnostic performances of the miRNA
signature identified, we fitted a multivariate logistic model selected
by maximizing the Akaike Information Criteria (AIC) and a
Relevance Vector Machine (RVM) model [35–37]. In contrast
with Support Vector Machine, RVM follow a Bayesian approach
giving a posteriori probability of the class. This makes the results
from the two approaches more directly comparable. ROC curve
and associated AUC were also computed for the logistic model.
A leave-one-out-cross-validation (LOOCV) approach was
adopted for assessing how the results of both the RVM and AIC
logistic regression predictive models would perform in practice.
Performances were summarized in terms of sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV),
and diagnostic accuracy.
Results
Study Population
A total of 311 subjects (159 males, 51.2%) were enrolled within
the TBnew group. As summarized in Figure 2 there were 56
healthy subjects, 109 individuals with LTBI (75 recent contacts of
active PTB cases; 34 non-recent contacts), 24 subjects affected by
other pulmonary infections (OPI), 32 EPTB and 90 PTB patients.
Subjects were recruited in Italy but were born in countries located
in the different World Health Organization (WHO) regions
(Figure 2). The TB CHILD group includes only individuals from
Tanzania and Uganda. A total of 186 subjects were enrolled (107
males, 57.5%): 49 healthy subjects, 64 PTB patients, and 73
patients with PTB and HIV co-infection. In the latter category the
median CD4+ cell count was 198.4 cells/mL (interquantile range:
277.1) compared with 707.7 cells/mL (interquantile range: 813.3)
of PTB subjects without HIV infection. H and PTB populations
were statistically comparable for mean age values of enrolled
subjects (p-values for H and PTB: 0.29, and 0.80, respectively).
Eight pools from the TBnew group, and 11 pools from the TB
CHILD group were considered for the analysis. We used a subset
of individuals to refine the miRNA signatures identified on pooled
specimens. Briefly, we performed individual serum analysis for 36
and 20 subjects for the TBnew, and the TB CHILD group,
respectively (details are reported in Table S1).
Normalization of qPCR Data
The TLDA is a 384-well microfluidic card containing dried
TaqManH primers and probes. Array A focuses on more highly
characterized miRNAs while array B contains many of the more
recently discovered miRNAs along with the miR* sequences. The
use of two panels (array A and array B) enables quantitation of
gene expression levels of up to 671 different miRNAs. This is
Table 3. Diagnostic performances of the serum miRNA signatures in the Relevance Vector Machine (RVM).
Serum miRNA signature (n) All (15) TBnew (10) TB CHILD (12)
n of individuals (H/PTB) 56 (28/28) 36 (18/18) 20 (10/10)
Sensitivity % (95% CI) 85.71 (68.51–94.30) 77.78 (54.78–91.00) 100.00 (72.25–100.00)
Specificity % (95% CI) 78.57 (60.46–89.79) 88.89 (67.20–96.90) 90.00 (59.58–98.21)
PPV % (95% CI) 80.00 (62.69–90.50) 87.50 (63.98–96.50) 90.91 (62.26–98.38)
NPV % (95% CI) 84.62 (66.47–93.85) 80.00 (58.40–91.93) 100.00 (70.08–100.00)
Diagnostic accuracy % (95% CI) 82.14 (70.16–90.00) 83.33 (68.11–92.13) 95.00 (76.39–99.11)
Likelihood ratio of a positive test % (95% CI) 4 (2.846–5.621) 7 (2.524–19.41) 10 (1.409–70.99)
Likelihood ratio of a negative test % (95% CI) 0.1818 (0.1087–0.3041) 0.25 (0.1508–0.4144) 0
The Table reports diagnostic performances already corrected for the leave-one-out cross validation (LOOCV).
doi:10.1371/journal.pone.0080149.t003
Table 4. Diagnostic performances of the serum miRNA signatures in the AIC logistic regression model.
Serum miRNA signature (n) All (15) TBnew (10) TB CHILD (12)
n of individuals (H/PTB) 56 (28/28) 36 (18/18) 20 (10/10)
Sensitivity % (95% CI) 71.43 (52.94–84.75) 72.22 (49.13–87.50) 100.00 (72.25–100.00)
Specificity % (95% CI) 82.14 (64.41–92.12) 88.89 (67.20–96.90) 100.00 (72.25–100.00)
PPV % (95% CI) 80.00 (60.87–91.14) 86.67 (62.12–96.26) 100.00 (72.25–100.00)
NPV % (95% CI) 74.19 (56.75–86.30) 76.19 (54.91–89.37) 100.00 (72.25–100.00)
Diagnostic accuracy % (95% CI) 76.79 (64.23–85.90) 80.56 (64.97–90.25) 100.00 (83.89–100.00)
Likelihood ratio of a positive test % (95% CI) 4 (2.599–6.156) 6.5 (2.302–18.35) undefined
Likelihood ratio of a negative test % (95% CI) 0.3478 (0.2672–0.4527) 0.3125 (0.2079–0.4696) 0
The Table reports diagnostic performances already corrected for the leave-one-out cross validation (LOOCV).
doi:10.1371/journal.pone.0080149.t004
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accomplished by loading the cDNA product onto the array for
PCR amplification and real-time analysis. MegaPlex Pools are
designed to detect and quantitate up to 380 microRNAs (miRNAs)
per pool in human species thanks to a set of stem-looped reverse
transcription primers (MegaPlex RT Primers) that enable the
simultaneous synthesis of cDNA and a set of miRNA-specific
forward and reverse primers (MegaPlex PreAmp Primers)
intended for use with very small quantities of starting material.
The primers enable the unbiased preamplification of the miRNA
cDNA target by PCR prior to loading the TaqManH MicroRNA
Array.
After the quantile normalization procedure, the Ct values of
four miRNAs (ath-miR159a, MammU6, RNU44, and RNU48)
detected by both array A and array B were compared. As showed
in Table S2, Ct values were consistent between ‘‘pools –
individuals’’, ‘‘array A – array B’’, and ‘‘TBnew – TB CHILD’’.
Normalized data from pooled and individual specimens are
reported in Table S3.
Analysis of Serum miRNA Profiles in Pooled Samples
Normalized qPCR data from pools showed 277 miRNAs
undetectable in the categories (H, PTB, LTBI, OPI, EPTB, and
PTB/HIV) from both groups (TBnew, and TB CHILD).
The mean Ct value for each miRNA was calculated and a one-
to-one comparison between different categories was carried out.
Residual values are available in Table S4.
Figure 3 summarizes the number of miRNAs outside the 1st and
3rd quantile tails of the distribution of the residuals obtained by
comparing two categories. The two percentiles considered, should
most probably contain the miRNAs that are significantly different
between the two compared categories. According to this qualita-
tive analysis based on the distribution of the residuals, between 120
and 172 serum miRNAs could allow to discriminate among the
categories considered in this study. For example, 134 miRNAs
showed to be relevant in differentiating LTBI and PTB, whereas
132 miRNAs would allow discriminating between PTB and OPI.
After filtering the pooled specimen results according to clinically
relevant categories, we identified putative serum miRNA signa-
tures defining MTB infection, active TB, pulmonary disease, or
any of the disease statuses considered in this study (Figure 4).
To optimize our approach, for the PTB and H categories, we
performed the analysis of individual sera.
Analysis of Serum miRNA Profiles in Individuals
Serum miRNA profiles from 18 H, and 18 PTB from TBnew
group as well as 10 H and 10 PTB from the TB CHILD group
were analyzed.
Out of the 671 miRNAs tested, 126 targets were detected in
80% of the subjects in at least one of the analyzed categories. As
reported in Table 1, 71 miRNAs showing a p-value ,0.05 were
identified: we could detect differences in serum miRNA profiles
between the TBnew and TB CHILD individuals (35 miRNAs,
49.3%), between H and PTB (29 miRNAs, 40.8%), and
Figure 6. Receiver Operating Characteristic (ROC) based on Akaike information criterion (AIC) logistic regression for the 15-miRNA
signature. AUC: area under the curve. The AIC model identified as the best performing miRNA signature the following: miR-let-7e, miR-146a, miR-16,
miR-25, miR-365, miR-451, miR-885-5p, miR-223*.
doi:10.1371/journal.pone.0080149.g006
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differences depending on both the population and the clinical
status (7 miRNAs, 9.9%). After checking for FDR (p-adj), twenty
miRNAs resulted to be significantly different between H and PTB
(let-7e, miR-10b, miR-127-5p, miR-146a, miR-148a, miR-16,
miR-185, miR-192, miR-193a-5p, miR-25, miR-365, miR-451,
miR-518d-3p, miR-532-5p, miR-590-5p, miR-660, miR-885-5p,
miR-223*, miR-30a, miR-30e). Complete results are available in
Table S5.
Pools vs Individuals
Out of the 20 miRNAs showing a significant p-adj in the study
on individuals (Table 1), 16 (80%) had already been identified as
‘‘relevant miRNA’’ in the analysis of pooled specimens (Figure 5).
Among those miRNAs, nine showed differences between H and
PTB pools in each group; four showed differences only in TB
CHILD pooled specimens, whereas three only in the pools from
TBnew group. Four miRNAs with a significant p-adj in the study on
individuals had not been detected as relevant by the first screening
on pooled specimens. Figure 5 shows that the analysis on pools
correctly excluded 429 out of 439 ‘‘not relevant’’ miRNAs from
further investigations.
Then, for the 16 miRNAs found to be relevant in the pooled
specimens analysis and significant (p-adj,0.05) in individual sera (let-
7e,miR-146a,miR-148a,miR-16,miR-192,miR-193a-5p,miR-25,
miR-365, miR-451, miR-532-5p,miR-590-5p, miR-660,miR-885-
5p,miR-223*,miR-30a), we compared the direction of the variation
(increase ordecrease) inpooledand singlePTBserumanalyses. From
this comparison we found that some miRNAs showed inconsistent
results between individual and pooled specimens (Table 2): eleven
miRNAs showed the same type of variation in individual and pooled
samples across both study groups considered, threemiRNAs showed
discordantvariationonly inTBneworTBCHILDpopulation,andone
showed discordant variation in both TBnew and TB CHILD groups.
Five and three targets were found to be associated only to the TB
CHILD and to theTBnew group, respectively. In conclusion, from the
combined analysis on pools and individuals, a total of 15 miRNAs
were identified as a signature for discriminating betweenHandPTB
(let-7e, miR-146a, miR-148a, miR-16, miR-192, miR-193a-5p,
miR-25, miR-365, miR-451, miR-532-5p, miR-590-5p, miR-660,
miR-885-5p, miR-223*, miR-30e).
Diagnostic Performances of the Identified Serum miRNA
Signature
We used two approaches to evaluate the diagnostic perfor-
mances of the identified serum miRNA signature: RVM model,
and AIC logistic regression analysis. Both were cross-validated by
the use of a LOOCV approach. All fifteen miRNAs (let-7e, miR-
146a, miR-148a, miR-16, miR-192, miR-193a-5p, miR-25, miR-
365, miR-451, miR-532-5p, miR-590-5p, miR-660, miR-885-5p,
miR-223*, miR-30e) were used to re-classify the 56 subjects
analyzed as single sera obtaining a diagnostic accuracy of 82% by
RVM, and of 77% by logistic regression. The diagnostic accuracy
increased up to 83% by RVM and 81% by logistic regression
when miRNAs identified as ‘‘TBnew-specific’’ (let-7e, miR-148a,
Figure 7. Receiver Operating Characteristic (ROC) based on Akaike information criterion (AIC) logistic regression for the 10-miRNA
signature specific for TBnew population. AUC: area under the curve. The AIC model identified as the best performing miRNA signature the
following: miR-let-7e, miR-192, miR-25, miR-451.
doi:10.1371/journal.pone.0080149.g007
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miR-16, miR-192, miR-193a-5p, miR-25, miR-365, miR-451,
miR-590-5p, miR-885-5p) re-classify TBnew single serum samples.
A similar increase was observed when the ‘‘TB CHILD-specific’’
signature (let-7e, miR-146a, miR-148a, miR-192, miR-193a-5p,
miR-451, miR-532-5p, miR-590-5p, miR-660, miR-885-5p, miR-
223*, miR-30e) was used on the 10 individual samples from TB
CHILD group (95% by RVM, and 100% by logistic regression,
respectively). Table 3 and Table 4 summarize the diagnostic
performances of the miRNA signatures achieved by the different
approaches used for the classification of subjects. AUCs for the
regression logistic analyses are reported in Figure 6, Figure 7, and
Figure 8.
Discussion
In TB biomarker research, published studies on highly
multiplexed assays focus on proteomics, gene expression, tran-
scriptomics, and miRNAs, as predictors of disease, disease
recurrence or drug resistant infection [38–47]. Our study on
serum miRNA signatures ascertains the value of these biomarkers
for TB disease classification, as previously reported by others [21–
23]. However, previous studies did not consider the impact of the
genetic makeup on the miRNA signatures: ethnicity, together with
age and gender, could influence the levels of circulating miRNAs
[48]. By the comparison of two populations with different genetic
makeup we showed that some population-specific miRNAs can
increase the diagnostic accuracy for active TB.
While much research is still focused on assessing the quality of
single biomarkers, there is an emerging interest in panels of
biomarkers composed of multiple candidate targets which are
neither specific nor sensitive when used as single tests, but which
show a good performance when used in combination. In this study
we used both RVM and logistic regression methods supported by a
LOOCV approach to evaluate the diagnostic performances of
serum miRNAs identified as a signature rather than as single
biomarkers. The presence of miRNAs detectable in at least the
80% of one category indicates a higher diagnostic index;
moreover, our filtering approach did not introduce biases in
detecting potential on/off miRNAs between categories. Indeed,
whenever a serum sample is tested for miRNA, its diagnostic
relevance will be attested by its level rather than by their presence/
absence in H and PTB categories.
To ascertain if a serum miRNA signature could discriminate
between different categories of patients, we used a restrictive
stratification screening approach to minimize the number of
possible biases. Despite subjects within the H category showed a
mean age lower than the other categories, we consider this to be
only a minor drawback of the study. Particular attention should be
reserved to specific subgroups (e.g. childhood and elderly) where
age would expect to have a bigger impact. Another possible
drawback could be the heterogeneity in terms of genetic
background (estimated on the basis of the country of birth) in
the TBnew group. This could partially explain lower performances
of the miRNA signature on this population. The results on pooled
specimens identified differences in serum miRNA profiles in the
Figure 8. Receiver Operating Characteristic (ROC) based on Akaike information criterion (AIC) logistic regression for the 12-miRNA
signature specific for TB CHILD population. AUC: area under the curve.
doi:10.1371/journal.pone.0080149.g008
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categories analyzed. Interestingly, according to our qualitative
analysis based on the Empirical Distribution Function of residuals,
serum miRNAs would allow not only to discriminate LTBI and
PTB, but also PTB from OPI and EPTB. Indeed, the 134
miRNAs showing relevant differences in serum level of LTBI and
PTB subjects include a smaller subset of miRNAs that could be
used as specific signature to discriminate between these two
categories. A similar approach could be applied for the 132
miRNAs showing relevant differences in serum levels of PTB and
OPI subjects and for the 124 miRNAs differentiating PTB and
EPTB subjects. Further studies on cohorts of LTBI, OPI and
EPTB individuals will allow to identify specific miRNA patterns
and to evaluate their diagnostic accuracy. The discriminatory
power of serum miRNAs observed is further supported by the fact
that the same findings have been confirmed in the two different
groups (namely TBnew and TB CHILD) for the signature identified
for the comparison H-PTB. Additionally, the use of pooled
specimens allowed halving the number of targets to be analyzed by
excluding miRNAs under the detection threshold or showing very
little changes across categories.
To refine our findings, we performed serum miRNA analysis on
individual sera from H and PTB subjects. Table 5 summarizes the
comparison between our results and previously published studies. In
the first study on circulating miRNAs as biomarkers for TB reported
by Fu and colleagues [21], it was demonstrated that 92 miRNAs
had significantly different levels in the sera of healthy controls vs
PTB subjects: 59 miRNAs were down-regulated and 33 miRNAs
were up-regulated in the serum of TB patients. One-by-one
comparison is not possible due to different analytical platforms
and normalization strategies, but some homologies between the
study by Fu and our results can be observed. For example, miRNAs
belonging the families let-7, miR-30, and miR-146 were found to be
significantly different between H and PTB in both studies. miRNAs
miR-590-5p, miR-185, miR-660, let-7e, miR-25, miR-146a, and
miR-885-5p showed to be differentially expressed between healthy
controls and PTB subject also in the study reported by Qi and
colleagues [22]. miR-197 which was observed to be slightly
increased in our study was also reported to be increased in sera
from pulmonary TB patients by Abd-El-Fattah and colleagues [23].
However, the previous studies did not consider the genetic
background of the subjects enrolled. Differently, in the present
study the inclusion of groups with different genetic background
allowed us to better define serum miRNA signatures associated to a
different (health) status. Indeed, subjects belonging to the same
status (i.e. H or PTB) showed different serum miRNA levels
between the TBnew and the TB CHILD groups in pooled specimens
(Table S4). Comparing individual sera from subjects belonging to
the two populations we found significant differences in the level of
several miRNAs (Table S5). Despite larger population-based studies
are still needed, our data support the hypothesis that the genetic
background could influence the specific serum miRNA profiles.
Interestingly, by matching miRNA signatures from pooled speci-
mens, individual specimens, and direction of variation (increase/
decrease) we identified 7 common discriminatory miRNAs (let-7e,
miR-148a, miR-192, miR-193a-5p, miR-451, miR-590-5p, miR-
885-5p) plus three miRNAs specific for the TBnew group (miR-16,
miR-25, miR-365), and five miRNAs specific for the TB CHILD
group (miR-146a, miR-532-5p, miR-660, miR-223*, miR-30e).
The diagnostic accuracy for each single miRNA was found to be
,75% (data not shown), while better results were achieved by using
the approach of ‘‘signatures’’: AUC values were above 0.90 and the
use of the entire fifteen-miRNAs signature provided a diagnostic
accuracy between 77% and 82% in a LOOCV approach (logistic
regression and RVM, respectively). Population-specific signatures
allowed to further improve classification accuracy (81–83% for
TBnew, and 95–100% for TB CHILD, respectively). As mentioned
before, serummiRNA signatures showed less efficiency in classifying
subjects belonging to the TBnew group. Our hypothesis is that,
despite the mild to moderate differences, the genetic background
heterogeneity of this group is likely affecting the classification
performances of the miRNA signature. The higher number of
miRNAs with discrepancy variations (in terms of increase/decrease)
between individual and pooled specimens provides some evidence
on the heterogeneity of the TBnew population.
As for the function of extracellular miRNAs, current evidences
suggest a regulatory role on the expression of target genes when taken
up by recipient cells, with the peculiar capability to act on several
targets at a time and to operate in a network with other extracellular/
intracellular miRNAs [17,19]. A ‘‘hormonal’’ role to extracellular
miRNAs was attributed [17,19]. If this interpretation proves to be
true, we could then be facing a major advancement in modern
biology not only for better understanding of biological complexity,
but also in terms of diagnostic and even therapeutic possibilities [49].
Target cells for extracellular miRNAs and related targeting
mechanism are poorly understood, thus careful interpretation of
circulating miRNA origin and function should be considered.
Here we described a serum miRNA signature discriminating H
and PTB subjects. Despite promising results, several challenges in
pre-analytical and analytical phases remain in the analysis of
circulating miRNAs. Accurate large-cohort studies are therefore
required to validate PTB-specific miRNA signatures, and to
identify miRNA signatures also for LTBI, EPTB and pathologies
(like pneumonia, cancer, HIV infection and sarcoidosis) often in
differential diagnosis with TB. The inclusion of different sets of
biomarkers (e.g. cytokines, antibodies) could also help in achieving
higher discrimination power amongst the closest categories.
Supporting Information
Table S1 Details on subjects included in pooled and
individual specimens analyzed in the study. H: healthy
Table 5. Comparison between the serum miRNA signature
found in the present and the miRNAs reported in the previous
studies.
miRNA Fu et al, 2011 Qi et al, 2012
hsa-let-7e-4395517 let-7 family let-7e, let-7 family
hsa-miR-146a-4373132 miR-146a miR-146a
hsa-miR-148a-4373130 – –
hsa-miR-16-4373121 – –
hsa-miR-192-4373108 – –
hsa-miR-193a-5p-4395392 – miR-193 family
hsa-miR-25-4373071 – miR-25
hsa-miR-365-4373194 miR-365 family –
hsa-miR-451-4373360 – –
hsa-miR-532-5p-4380928 – miR-532 family
hsa-miR-590-5p-4395176 – miR-590-5p
hsa-miR-660-4380925 – miR-660
hsa-miR-885-5p-4395407 – miR-885-5p
hsa-miR-223*-4395209 – miR-223 family
hsa-miR-30e-4395334 miR-30 family miR-30 family
doi:10.1371/journal.pone.0080149.t005
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controls; LTBI: latent tuberculosis infection; PTB: pulmonary
active tuberculosis; EPTB: active extra-pulmonary tuberculosis;
OPI: other pulmonary infections; PTB/HIV: PTB in HIV-
positive. SD: standard deviation.
(XLSX)
Table S2 Comparison of the Ct values among the four
miRNAs detected in both array A and array B types
between different populations (TBnew, TB CHILD) and
different specimens (individual sera, pooled sera). Mean
Ct values are reported together with the standard deviation after
quantile normalization.
(XLSX)
Table S3 Normalized Ct values obtained from individ-
ual and pooled specimens after quantile normalization.
(XLSX)
Table S4 Complete data analysis on pooled specimens.
The Table reports residual values obtained by each comparison
performed between the categories. Relevant differences are
highlighted.
(XLSX)
Table S5 Complete data analysis on individual speci-
mens. The Table reports the p-value for the following
comparison on individual specimens: TBnew vs TB CHILD, and
healthy control (H) vs pulmonary active tuberculosis (PTB). P-
adjusted (p-adj) is reported for the comparison H vs PTB. Values
,0.05 are highlighted. na: not applicable (miRNAs not detected in
at least 80% of subjects in at least one of the category considered
where not included in the analysis).
(XLSX)
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